[go: up one dir, main page]

LT3137169T - Lizinui specifinės demetilazės-1 inhibitoriai - Google Patents

Lizinui specifinės demetilazės-1 inhibitoriai

Info

Publication number
LT3137169T
LT3137169T LTEPPCT/US2015/028635T LT15028635T LT3137169T LT 3137169 T LT3137169 T LT 3137169T LT 15028635 T LT15028635 T LT 15028635T LT 3137169 T LT3137169 T LT 3137169T
Authority
LT
Lithuania
Prior art keywords
demetylase
lysine
inhibitors
specific
specific demetylase
Prior art date
Application number
LTEPPCT/US2015/028635T
Other languages
English (en)
Inventor
Young Chen
Toufike Kanouni
Stephen W. Kaldor
Jeffrey Alan Stafford
James Veal
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of LT3137169T publication Critical patent/LT3137169T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LTEPPCT/US2015/028635T 2014-05-01 2015-04-30 Lizinui specifinės demetilazės-1 inhibitoriai LT3137169T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987354P 2014-05-01 2014-05-01
PCT/US2015/028635 WO2015168466A1 (en) 2014-05-01 2015-04-30 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
LT3137169T true LT3137169T (lt) 2022-04-11

Family

ID=54354743

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2015/028635T LT3137169T (lt) 2014-05-01 2015-04-30 Lizinui specifinės demetilazės-1 inhibitoriai

Country Status (32)

Country Link
US (9) US9255097B2 (lt)
EP (1) EP3137169B1 (lt)
JP (1) JP6493890B2 (lt)
KR (1) KR102400920B1 (lt)
CN (1) CN106659914B (lt)
AR (1) AR100251A1 (lt)
AU (1) AU2015253040B2 (lt)
BR (1) BR112016025248B1 (lt)
CA (1) CA2947283C (lt)
CL (1) CL2016002736A1 (lt)
CY (1) CY1124959T1 (lt)
DK (1) DK3137169T3 (lt)
EA (1) EA036672B8 (lt)
ES (1) ES2903423T3 (lt)
HR (1) HRP20220096T1 (lt)
HU (1) HUE057895T2 (lt)
IL (1) IL248505B (lt)
LT (1) LT3137169T (lt)
MX (1) MX2016014253A (lt)
NI (1) NI201600165A (lt)
PE (1) PE20161438A1 (lt)
PH (1) PH12016502179A1 (lt)
PL (1) PL3137169T3 (lt)
PT (1) PT3137169T (lt)
RS (1) RS62874B1 (lt)
SA (2) SA516380201B1 (lt)
SG (1) SG11201609033TA (lt)
SI (1) SI3137169T1 (lt)
SM (1) SMT202200066T1 (lt)
TW (1) TWI676620B (lt)
WO (1) WO2015168466A1 (lt)
ZA (1) ZA201607613B (lt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
AU2015253040B2 (en) * 2014-05-01 2020-04-09 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
LT3164380T (lt) * 2014-07-03 2022-06-27 Celgene Quanticel Research, Inc. Lizinui specifiniai demetilazės-1 inhibitoriai
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EP3310774B1 (en) 2015-06-19 2020-04-29 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
PT3371152T (pt) 2015-11-05 2021-02-01 Celgene Quanticel Res Inc Composições compreendendo um inibidor de lisina específica desmetilase-1 com um anel de pirimidina e sua utilização no tratamento do cancro
SG11201804121RA (en) 2015-11-27 2018-06-28 Taiho Pharmaceutical Co Ltd Novel biphenyl compound or salt thereof
US9809541B2 (en) 2015-12-29 2017-11-07 Mirati Therapeutics, Inc. LSD1 inhibitors
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
AU2017310423B2 (en) 2016-08-10 2022-02-03 Celgene Quanticel Research, Inc. Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
JP2019532953A (ja) * 2016-09-30 2019-11-14 ノバルティス アーゲー 増強された有効性を有する免疫エフェクター細胞治療
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
US20180290977A1 (en) 2017-03-30 2018-10-11 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
EP3632897A4 (en) 2017-05-26 2020-10-21 Taiho Pharmaceutical Co., Ltd. NEW BIPHENYL COMPOUND OR SALT OF THE SAME
PL3632443T3 (pl) * 2017-05-26 2023-09-18 Taiho Pharmaceutical Co., Ltd. Środek wzmacniający działanie przeciwnowotworowe wykorzystujący związek bifenylowy
WO2018221555A1 (ja) 2017-05-31 2018-12-06 大鵬薬品工業株式会社 Ｉｎｓｍ１の発現に基づくｌｓｄ１阻害剤の治療効果の予測方法
EP3661510B1 (en) 2017-08-03 2024-10-09 Oryzon Genomics, S.A. Methods of treating behavior alterations
CN112368272B (zh) * 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
CN109668987A (zh) * 2019-02-27 2019-04-23 浙江华贝药业有限责任公司 一种3-氨基哌啶二盐酸盐对映异构体测定分析方法
EP3941465A1 (en) 2019-03-20 2022-01-26 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
EP3941466A1 (en) 2019-03-20 2022-01-26 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
CN114727996A (zh) 2019-06-20 2022-07-08 细胞基因公司 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
EP3994280A1 (en) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US20220411381A1 (en) * 2019-10-01 2022-12-29 Bayer Aktiengesellschaft Pyrimidinedione derivatives
KR20220151637A (ko) * 2020-03-06 2022-11-15 셀젠 콴티셀 리서치, 인크. Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합
JP2023529367A (ja) 2020-06-05 2023-07-10 セルジーン・クオンティセル・リサーチ・インコーポレイテッド 前立腺がんの治療方法
WO2022199662A1 (zh) * 2021-03-24 2022-09-29 四川汇宇制药股份有限公司 一种多环化合物及其应用
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024119067A1 (en) 2022-12-02 2024-06-06 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US6489344B1 (en) * 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2450934A1 (en) * 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
EP1575940B1 (en) 2002-11-21 2011-10-05 Novartis AG 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US8466163B2 (en) * 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
DK2323992T3 (en) * 2008-07-29 2016-10-31 Boehringer Ingelheim Int 5-alkynyl pyrimidines
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2568812B1 (en) * 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9527805B2 (en) 2010-09-10 2016-12-27 Robert A. Casero Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
CA2831143C (en) 2011-03-25 2019-05-21 Glaxosmithkline Intellectual Property Development Limited Cyclopropylamines as lsd1 inhibitors
WO2013175789A1 (ja) 2012-05-24 2013-11-28 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
CN105189504B (zh) 2013-03-11 2017-07-18 艾伯维公司 稠合四环溴结构域抑制剂
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
CA2927567C (en) 2013-10-18 2022-04-26 Celgene Quanticel Research, Inc. Bromodomain inhibitors
CA2933480C (en) * 2013-12-11 2022-08-23 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
AU2015253040B2 (en) * 2014-05-01 2020-04-09 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2016014859A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
PT3371152T (pt) * 2015-11-05 2021-02-01 Celgene Quanticel Res Inc Composições compreendendo um inibidor de lisina específica desmetilase-1 com um anel de pirimidina e sua utilização no tratamento do cancro

Also Published As

Publication number Publication date
PL3137169T3 (pl) 2022-02-28
KR20160144506A (ko) 2016-12-16
DK3137169T3 (da) 2022-02-14
US9573930B2 (en) 2017-02-21
NI201600165A (es) 2017-03-13
US20170349555A1 (en) 2017-12-07
IL248505B (en) 2021-01-31
US10023543B2 (en) 2018-07-17
CN106659914B (zh) 2020-06-19
WO2015168466A1 (en) 2015-11-05
US10654810B2 (en) 2020-05-19
MX2016014253A (es) 2017-02-08
US20170349556A1 (en) 2017-12-07
US20220153706A1 (en) 2022-05-19
US10207999B2 (en) 2019-02-19
US20160130247A1 (en) 2016-05-12
RS62874B1 (sr) 2022-02-28
EA036672B8 (ru) 2021-01-13
KR102400920B1 (ko) 2022-05-20
TWI676620B (zh) 2019-11-11
CL2016002736A1 (es) 2017-06-23
AR100251A1 (es) 2016-09-21
TW201623254A (zh) 2016-07-01
AU2015253040A8 (en) 2017-06-15
BR112016025248A2 (pt) 2018-06-19
EA036672B1 (ru) 2020-12-07
SA519410025B1 (ar) 2022-06-01
ES2903423T3 (es) 2022-04-01
EP3137169B1 (en) 2021-11-10
EP3137169A1 (en) 2017-03-08
US20200231549A1 (en) 2020-07-23
CA2947283C (en) 2023-01-24
CN106659914A (zh) 2017-05-10
AU2015253040A1 (en) 2016-11-24
JP2017514830A (ja) 2017-06-08
PE20161438A1 (es) 2017-01-18
EA201692079A1 (ru) 2017-04-28
CY1124959T1 (el) 2023-01-05
ZA201607613B (en) 2017-11-29
BR112016025248B1 (pt) 2022-12-13
PH12016502179A1 (en) 2017-02-13
WO2015168466A8 (en) 2016-11-24
US11084793B2 (en) 2021-08-10
NZ725914A (en) 2023-09-29
AU2015253040B2 (en) 2020-04-09
US20170114024A1 (en) 2017-04-27
JP6493890B2 (ja) 2019-04-03
SI3137169T1 (sl) 2022-04-29
US9776974B2 (en) 2017-10-03
SA516380201B1 (ar) 2019-11-20
HRP20220096T1 (hr) 2022-04-15
SMT202200066T1 (it) 2022-03-21
US20160152595A1 (en) 2016-06-02
SG11201609033TA (en) 2016-11-29
EP3137169A4 (en) 2018-01-10
HUE057895T2 (hu) 2022-06-28
PT3137169T (pt) 2022-01-25
CA2947283A1 (en) 2015-11-05
US9255097B2 (en) 2016-02-09
US9771329B2 (en) 2017-09-26
US11987560B2 (en) 2024-05-21
US20150315187A1 (en) 2015-11-05
IL248505A0 (en) 2016-12-29
US20180325900A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
LT3303334T (lt) Tirozinkinazės inhibitoriai
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
LT3511319T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3442972T3 (da) Bromdomænehæmmere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3006072T3 (da) Karadgang
DK3119396T3 (da) Muscarinreceptoragonister
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
NL301228I2 (nl) nirsevimab
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3341379T3 (da) EZH2-hæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DE112015001664A5 (de) Betätigungsaktuator
DK3183340T3 (da) Termolabile exonukleaser
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3009858T3 (da) Skyradar